Imunon Presents OVATION 3 Ovarian Cancer Study Data: IMNN-001 Immunotherapy Progress and Milestones

Imunon, Inc. discussed IMNN-001 immunotherapy progress and milestones in the OVATION 3 ovarian cancer study, aiming to be the first immunotherapy approved for frontline advanced ovarian cancer. The company showcased compelling data and updated on the ongoing Phase III trial, bringing them closer to achieving their goal.